Official Journal Health Science of Prince of Songkla University

  • Home
  • Search
  • Current
  • Archives
  • Announcements
  • Guide for Authors
  • Publication Ethics
  • Editorial Board
  • Submit
  • About
  • Contact
  • Online-first Articles
  • EVENTS
  • Review Process
Home > Vol 42, No 4 (2024) > Nawalerspanya

Exacerbation of Autoimmune Hepatitis following Inactivated SARS-CoV-2 Vaccination

Siwanon Nawalerspanya, Kontee Wongseree, Pimsiri Sripongpun, Naichaya Chamroonkul, Apichat Kaewdech

Abstract

Autoimmune hepatitis (AIH) is a rare condition that has seldom been reported being reactivated by a coronavirus disease 2019 (COVID-19) vaccination, especially from an inactivated vaccine. This report presents the case of a 64-year-old male with quiescent AIH cirrhosis who exhibited jaundice and constitutional symptoms for three days at two weeks following his second dose of an inactivated vaccine. The patient had complied well with a four-year immunosuppressive medication regimen to treat AIH which maintained normalized liver enzymes. He also abstained from using herbal supplements. At his presentation, his liver chemistry showed acute hepatocellular jaundice, with histology revealing active AIH. Following extensive testing, he was diagnosed with an AIH exacerbation triggered by the COVID-19 vaccine. His symptoms improved following treatment with higher doses of immunosuppressive agents. This report underscores the potential effect of the COVID-19 vaccine on reactivating well-controlled AIH.

 

 Keywords

autoimmune hepatitis (AIH); COVID-19; liver; SARS-CoV-2; vaccination

 Full Text:

PDF

References

Zhao J, Zhao S, Ou J, Zhang J, Lan W, Guan W, et al. Covid-19: coronavirus vaccine development updates. Front Immunol 2020;11:602256.

Freeman D, Loe BS, Yu LM, Freeman J, Chadwick A, Vaccari C, et al. Effects of different types of written vaccination information on COVID-19 vaccine hesitancy in the UK (OCEANS-III): a single-blind, parallel-group, randomised controlled trial. Lancet Public Health 2021;6:e416–27.

Teijaro JR, Farber DL. COVID-19 vaccines: modes of immune activation and future challenges. Nat Rev Immunol 2021;21:195–7.

Dighriri IM, Alhusayni KM, Mobarki AY, Aljerary IS, Alqurashi KA, Aljuaid FA, et al. Pfizer-biontech covid-19 vaccine (bnt162b2) side effects: a systematic review. Cureus 2022;14:e23526.

Camacho-Domínguez L, Rodríguez Y, Polo F, Restrepo Gutierrez JC, Zapata E, Rojas M, et al. COVID-19 vaccine and autoimmunity. a new case of autoimmune hepatitis and review of the literature. J Transl Autoimmun 2022;5:100140.

De Michele M, Kahan J, Berto I, Schiavo OG, Iacobucci M, Toni D, et al. Cerebrovascular Complications of COVID-19 and COVID-19 Vaccination. Circ Res 2022;130:1187–203.

Avci E, Abasiyanik F. Autoimmune hepatitis after SARS-CoV-2 vaccine: New-onset or flare-up? J Autoimmun 2021;125:102745.

Bril F, Al Diffalha S, Dean M, Fettig DM. Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: causality or casualty? J Hepatol. 2021;75:222–4.

Clayton-Chubb D, Schneider D, Freeman E, Kemp W, Roberts SK. Autoimmune hepatitis developing after the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccine. J Hepatol 2021 ;75:1249–50.

Garrido I, Lopes S, Simões MS, Liberal R, Lopes J, Carneiro F, et al. Autoimmune hepatitis after COVID-19 vaccine - more than a coincidence. J Autoimmun 2021;125:102741.

Rela M, Jothimani D, Vij M, Rajakumar A, Rammohan A. Auto-immune hepatitis following COVID vaccination. J Autoimmun 2021;123:102688.

Domerecka W, Kowalska-Kępczyńska A, Michalak A, Homa-Mlak I, Mlak R, Cichož-Lach H, et al. Etiopathogenesis and diagnostic strategies in autoimmune hepatitis. Diagnostics (Basel) 2021;11:1418.

European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Autoimmune hepatitis. J Hepatol 2015;63:971–1004.

Perumalswami P, Peng L, Odin JA. Vaccination as a triggering event for autoimmune hepatitis. Semin Liver Dis 2009;29:331–4.

Codoni G, Kirchner T, Engel B, Villamil AM, Efe C, Stättermayer AF, et al. Histological and serological features of acute liver injury after SARS-CoV-2 vaccination. JHEP Rep 2023;5:100605.

DOI: http://dx.doi.org/10.31584/jhsmr.20241030

Refbacks

  • There are currently no refbacks.
Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

SUBMIT A PAPER

JHSMR accepts online submission through

AHR-iCON 2024

Journal Metrics


2020
Acceptance rate: 52%
2021
Acceptance rate: 27.8%
2022 (March)
Acceptance rate: 15.6%
2023 (June)
Acceptance rate: 23.6%


Submission to final decision
74 days

Acceptance to publication
40 days

SCImago Journal & Country Rank

About The Authors

Siwanon Nawalerspanya
Department of Internal Medicine, Phaholponpayuhasena Hospital, Kanchanaburi 71000, Thailand. Gastroenterology and Hepatology Unit, Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla 90110,
Thailand

Kontee Wongseree
Gastroenterology and Hepatology Unit, Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla 90110,
Thailand

Pimsiri Sripongpun
Gastroenterology and Hepatology Unit, Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla 90110,
Thailand

Naichaya Chamroonkul
Gastroenterology and Hepatology Unit, Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla 90110,
Thailand

Apichat Kaewdech
Gastroenterology and Hepatology Unit, Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla 90110,
Thailand

Article Tools
Abstract
Print this article
Indexing metadata
How to cite item
Email this article (Login required)
Email the author (Login required)

Supported by

 

JHSMR now Indexed in



Scopus logo.svg






Image result for crossref





PSUMJ Homepage

Keywords COVID-19 SARS-CoV-2 Thailand Vietnam anxiety children computed tomography depression diabetes elderly factors hypertension knowledge mental health mortality prevalence quality of life risk factor risk factors treatment validity
Journal Content

Browse
  • By Issue
  • By Author
  • By Title
Font Size

Open Journal Systems